Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

350.00DKK
10:59am EDT
Change (% chg)

kr.5.40 (+1.57%)
Prev Close
kr.344.60
Open
kr.345.50
Day's High
kr.350.00
Day's Low
kr.343.75
Volume
1,655,321
Avg. Vol
2,448,869
52-wk High
kr.350.00
52-wk Low
kr.265.15

Latest Key Developments (Source: Significant Developments)

Novo Nordisk H1 Operating Profit At DKK 27.69 Bln, Above Estimates
Friday, 9 Aug 2019 01:31am EDT 

Aug 9 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK'S OPERATING PROFIT INCREASED BY 12% IN DANISH KRONER AND BY 6% AT CONSTANT EXCHANGE RATES (CER) IN THE FIRST SIX MONTHS OF 2019.H1 SALES 59.33 BILLION DKK VERSUS 58.72 BILLION DKK SEEN IN REFINITIV POLL.H1 SALES OF OZEMPIC(®) WERE DKK 3,750 MILLION AND IT HAS NOW BEEN LAUNCHED IN 21 COUNTRIES..SEES 219 SALES GROWTH 4-6% VERSUS PREVIOUSLY 2-5% AT CER.H1 OPERATING PROFIT 27.69 BILLION DKK VERSUS 27.21 BILLION DKK SEEN IN REFINITIV POLL.IN USA, NEW-TO-BRAND PRESCRIPTION MARKET SHARE FOR OZEMPIC(®) IS NOW 35%, BRINGING NOVO NORDISK'S COMBINED GLP-1 NEW-TO-BRAND PRESCRIPTION MARKET SHARE TO 53%.SEES 2019 OPERATING PROFIT GROWTH 4-6% VERSUS PREVIOUSLY 2-6% AT CER.CEO SAYS WE ARE PLEASED WITH SALES GROWTH IN FIRST HALF OF 2019, WHICH IS DRIVEN BY ALL REGIONS IN INTERNATIONAL OPERATIONS.LAUNCH OF OZEMPIC(®) IS EXPANDING GLP-1 MARKET, AND WE ARE ENCOURAGED BY POSITIVE MARKET RECEPTION IN BOTH NORTH AMERICA AND EUROPE..WE CONTINUE TO INVESTIGATE CLINICAL BENEFITS OF SEMAGLUTIDE ACROSS MULTIPLE INDICATIONS.SALES OF GLP-1 PRODUCTS FOR TYPE 2 DIABETES (VICTOZA® AND OZEMPIC® ) INCREASED BY 24% MEASURED IN DANISH KRONER AND BY 18% AT CER TO DKK 14,887 MILLION..H1 VICTOZA SALES DKK 11.14 BILLION.H1 SALES IN NORTH AMERICA OPERATIONS INCREASED BY 5% MEASURED IN DANISH KRONER AND DECREASED BY 2% AT CER..  Full Article

FDA Approves New Treatment For Pediatric Patients With Type 2 Diabetes
Monday, 17 Jun 2019 03:26pm EDT 

June 17 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW TREATMENT FOR PEDIATRIC PATIENTS WITH TYPE 2 DIABETES.U.S. FDA - APPROVED VICTOZA (LIRAGLUTIDE) INJECTION FOR TREATMENT OF PEDIATRIC PATIENTS 10 YEARS OR OLDER WITH TYPE 2 DIABETES.FDA - APPROVAL OF VICTOZA WAS GRANTED TO NOVO NORDISK.U.S. FDA - PRESCRIBING INFORMATION FOR VICTOZA INCLUDES BOXED WARNING TO ADVISE ABOUT INCREASED RISK OF THYROID C-CELL TUMORS.  Full Article

Novo Nordisk Submits Oral Semaglutide For EU Regulatory Approval
Friday, 26 Apr 2019 04:58am EDT 

April 26 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK FILES FOR EU REGULATORY APPROVAL OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES.SAYS ORAL SEMAGLUTIDE HAS NOW BEEN SUBMITTED FOR REGULATORY APPROVAL IN US, EU AND CANADA.  Full Article

Novo Nordisk Announces Reduction Of Share Capital
Wednesday, 24 Apr 2019 12:27pm EDT 

April 24 (Reuters) - Novo Nordisk A/S ::Novo Nordisk A/S - REDUCTION OF SHARE CAPITAL.CO CANCELLED B SHARES AT A NOMINAL VALUE OF DKK 10,000,000.REGISTERED IMPLEMENTATION OF REDUCTION OF SHARE CAPITAL WITH DANISH BUSINESS AUTHORITY AND CANCELLED B SHARES AT NOMINAL VALUE OF DKK 10 MILLION.AT CO'S ANNUAL GENERAL MEETING ON 21 MARCH, IT WAS DECIDED TO REDUCE CO'S B SHARE CAPITAL FROM DKK 382.5 MILLION TO DKK 372.5 MILLION.REDUCTION OF SHARE CAPITAL WILL NOT AFFECT NOVO NORDISK'S SHARE REPURCHASE PROGRAMME WHICH WILL CONTINUE AS PREVIOUSLY ANNOUNCED.AFTER REDUCTION CO'S SHARE CAPITAL IS NOMINALLY DKK 480 MILLION, DIVIDED INTO A SHARE OF NOMINALLY DKK 107,487,200, B SHARE OF NOMINALLY DKK 372,512,800.  Full Article

Novo and Gilead Intent To Initiate Clinical Collaboration in NASH
Friday, 12 Apr 2019 04:01am EDT 

April 12 (Reuters) - Novo Nordisk NOVOB.CO::GILEAD SCIENCES AND NOVO NORDISK ANNOUNCE INTENT TO INITIATE A CLINICAL COLLABORATION IN NASH.THE COMPANIES INTEND TO COLLABORATE ON A CLINICAL TRIAL COMBINING COMPOUNDS FROM THEIR RESPECTIVE PIPELINES IN NONALCOHOLIC STEATOHEPATITIS (NASH).THE COMPANIES ARE ALSO EXPLORING THE POTENTIAL TO COLLABORATE ON PRECLINICAL RESEARCH TO ADVANCE UNDERSTANDING OF THE DISEASE.CILOFEXOR AND FIRSOCOSTAT, ALONE OR IN COMBINATION, ARE INVESTIGATIONAL COMPOUNDS AND ARE NOT APPROVED BY THE U.S. FOOD & DRUG ADMINISTRATION (FDA) OR ANY OTHER REGULATORY AUTHORITY.  Full Article

Novo Nordisk To Invest DKK 650 Million In Denmark Production Facilities
Friday, 29 Mar 2019 07:03am EDT 

March 29 (Reuters) - NOVO NORDISK A/S SAYS ::SAYS INVESTS DKK 650 MILLION IN UPGRADINGAND EXPANDING PRODUCTION FACILITIES IN KALUNDBORG.THE FACILITIES IN QUESTION ARE CURRENTLY MANUFACTURING A RANGE OF PRODUCTS FOR DIABETES TREATMENT AND WILL BE REBUILT TO ALLOW FOR FUTURE PRODUCTION OF THE NEXT GENERATION OF PRODUCTS.SAYS THE PROJECTS ARE EXPECTED TO BE COMPLETED IN 2020.SINCE THE TURN OF THE MILLENNIUM ALONE, NOVO NORDISK HAS INVESTED MORE THAN DKK 15 BILLION IN KALUNDBORG.  Full Article

Novo Nordisk Settles U.S. Patent Litigation Case On Victoza With Teva
Monday, 18 Mar 2019 07:02am EDT 

March 18 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK SETTLES U.S. PATENT LITIGATION CASE ON VICTOZA® (LIRAGLUTIDE) WITH TEVA.SAYS TEVA IS LICENSED TO LAUNCH A GENERIC VERSION OF VICTOZAAS OF 22 DECEMBER 2023.UNDER CERTAIN CIRCUMSTANCES TEVA COULD LAUNCH A GENERIC VERSION OF VICTOZA(®) EARLIER, BUT NOT BEFORE 22 MARCH 2023, UNLESS VICTOZA(®) PATENTS ARE NO LONGER IN FORCE OR THERE IS ANOTHER GENERIC VERSION OF VICTOZA(®) ON MARKET.SAYS IF NOVO NORDISK IS GRANTED SIX MONTHS PAEDIATRIC EXTENSION FOR VICTOZA(®), ALL ABOVE-MENTIONED TIMELINES WILL BE EXTENDED BY SIX MONTHS.SAYS - AGREEMENT IS SUBJECT TO REVIEW BY US FEDERAL TRADE COMMISSION AND US DEPARTMENT OF JUSTICE.  Full Article

Novo Nordisk Files For Fiasp Label Update In US, Europe
Friday, 1 Mar 2019 07:00am EST 

March 1 (Reuters) - NOVO NORDISK A/S ::FILES FOR A LABEL UPDATE FOR FIASP® TO THE EMA AND THE FDA SEEKING APPROVAL FOR USE IN CHILDREN AND ADOLESCENTS.SAYS WE ANTICIPATE A RESPONSE FROM EMA LATER THIS YEAR, AND FROM FDA IN EARLY 2020.  Full Article

Novo Nordisk Proposes Heineken CFO Joins Board
Friday, 22 Feb 2019 02:02am EST 

Feb 22 (Reuters) - Novo Nordisk A/S ::SAYS BOARD OF DIRECTORS PROPOSES RE-ELECTION OF ALL CURRENT BOARD MEMBERS.SAYS BOARD OF DIRECTORS PROPOSES ELECTION OF LAURENCE DEBROUX AT ANNUAL GENERAL MEETING.SAYS LAURENCE DEBROUX IS GROUP CHIEF FINANCIAL OFFICER AND MEMBER OF EXECUTIVE BOARD OF HEINEKEN.  Full Article

Abbott And Novo Nordisk Partner To Provide Integrated Digital Solution To People With Diabetes Using Insulin
Wednesday, 20 Feb 2019 09:00am EST 

Feb 20 (Reuters) - Abbott Laboratories ::ABBOTT AND NOVO NORDISK ENTER PARTNERSHIP TO PROVIDE INTEGRATED DIGITAL SOLUTION TO PEOPLE WITH DIABETES USING INSULIN.ABBOTT - PARTNERSHIP TO INTEGRATE INSULIN DOSE DATA FROM NOVO NORDISK CONNECTED PENS INTO DIGITAL HEALTH TOOLS COMPATIBLE WITH FREESTYLE LIBRE SYSTEM.  Full Article

Photo

Novo Nordisk contests Danish lawsuit claiming $1.75 billion

COPENHAGEN Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement.